Dx Dialogues: The impact of next-generation sequencing on clinical utility

Sanjay Juneja, MD, talks through the impact of next-generation sequencing in both somatic and germline testing.

Transcript

00:00

Genetic testing now plays a central role in identifying inherited cancer risk and actionable tumor mutations.

00:06

[UPBEAT MUSIC] Next generation sequencing allows simultaneous analysis

00:14

of multiple genes, improving both efficiency and clinical utility efficiency because you

00:20

can check all of the things that may be incriminated or responsible for making that cancer a cancer, if it's a somatic test, or germline test

00:29

to see all of the things that can be playing a role on what you can expect the cancer to do or how to behave, as well as how to treat it.

00:36

The other part is the clinical utility, meaning not just for the treatments that are options that could vary if you have an inherited mutation,

00:44

but also, it can help you do clinical trials because we can study more of these molecular biomarkers or actionable biomarkers to see if additional therapies can

00:53

be either designed or more effective than current standard of care. [AUDIO LOGO]